During a clinical trial, around 83% (10 out of 12) of patients who received a full dose of Zimislecel achieved complete ...

The American Diabetes Association, now endorses automated insulin delivery (AID) systems as the leading approach for ...

Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...

For adult women with overweight or obesity and T2D, replacing diet beverages with water is associated with greater weight loss and T2D remission.

Women with diabetes who were overweight or had obesity lost more weight and had greater odds of diabetes remission when ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

Medscape Education is a proud sponsor of the inaugural 2025 Cholestatic Liver Disease Summit, taking place June 26–28 in ...

As Ohio cuts off state employees' coverage of medications for weight loss, a lawmaker who has benefited from the drugs wants to bring them back.

Research shows heart attack deaths have plummeted by nearly 90% since 1970, while deaths from heart failure and arrhythmias ...